癌症是严重危害人类健康的重大疾病.近年来,免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)已经改变了多种实体肿瘤的治疗模式.尽管初始治疗效果显著,然而这种疗法的耐药问题已逐渐显现.深入了解ICIs耐药的机制显得尤为重要.肿瘤微环境(Tumor microenvironment,TME)中的中性粒细胞在程序性细胞死亡蛋白-1(Programmed cell death protein-1,PD-1)及其配体抑制剂耐药中起着关键作用.因此,重塑肿瘤相关中性粒细胞(Tumor-associated neutro-phils,TANs)不仅可以增强抗肿瘤免疫反应,而且可以在改善患者预后方面做出贡献.本文旨在探讨TANs在ICIs耐药中的潜在作用,并总结当前为克服ICIs耐药所开展的各项努力.
Research progress of tumor-associated neutrophils in immune checkpoint inhibitors resistance
Cancer is a major disease that seriously endangers human health.In recent years,immune checkpoint inhibitors(ICIs)have changed the paradigm of treatment for various solid tumors.Although the initial treatment effect is significant,the issue of drug resistance in this therapy has gradually become apparent.It is particularly important to have a deep understanding of the mecha-nisms of ICIs resistance.Neutrophils in the tumor microenvironment(TME)play a critical role in the resistance of programmed cell death protein-1(PD-1)and its ligand inhibitors.Thus,remodeling tumor-associated neutrophils(TANs)can not only enhance the anti-tumor immune response,but also contribute to improving patient prognosis.This article aims to explore the potential role of TANs in ICIs resistance and summarize current efforts to overcome ICIs resistance.
NETL
NSTL
万方数据
